TVM Capital Healthcare announces investment in Human Longevity for supporting disease prevention and healthy ageing

TVM Capital Healthcare, an international healthcare expansion and growth capital firm, has announced a recent equity investment in San Francisco-based Human Longevity, Inc. The investment will support the company's growth within the US market, as well as its expansion into the Kingdom of Saudi Arabia and Southeast Asia.

Founded by Dr J. Craig Venter, one of the pioneers of the human genome sequencing effort, HLI has proprietary tools for the detection of gene-disease associations, including HLI's artificial intelligence health risk and recommendation platform, and provides its clients with pre-symptomatic diagnosis and customised treatments, preempting disease at a very early stage and maximising health outcomes.

In short, HLI is transforming healthcare from a reactive practice to one that is predictive, proactive, and preventative, which not only enhances the quality of lives of individuals but improves the efficiency and efficacy of the entire healthcare system.

TVM Capital Healthcare brings extensive global investment experience combined with operating experience in the Middle East and Southeast Asia and a track record of building innovative healthcare companies. Through this investment provided by the Saudi Arabia-focused TVM Healthcare Afiyah Fund LP, which closed earlier this year and is the largest growth capital fund of its kind in the region, the firm will support HLI in its expansion, initially with a special focus on market entry in the Kingdom.

The country's Vision 2030 and Health Sector Transformation Programme call for an evolution of "sick care" to true "health care," focusing on the most critical fields of oncology, neurology, metabolic syndrome, and diabetes, as well as cardiovascular and autoimmune disease.